
The New England Journal of Medicine | Research & Review Articles on ...
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
First-Line Camizestrant for Emerging - The New England Journal of …
Jun 1, 2025 · Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced …
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured …
Survival of Transplanted Allogeneic Beta Cells with No ...
Aug 4, 2025 · The need to suppress a patient’s immune system after the transplantation of allogeneic cells is associated with wide-ranging side effects. We report the outcomes of transplantation of ...
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
Apr 8, 2025 · Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple …
A Crossover Trial of Hospital-Wide Lactated Ringer’s Solution versus ...
Jun 12, 2025 · Whether lactated Ringer’s solution is clinically superior to normal saline for routine intravenous administration of fluids is uncertain. In an open-label, two-period, two-sequence, cross ...
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous ...
Mar 11, 2026 · Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk …
Zongertinib in Previously Treated - The New England Journal of Medicine
Apr 28, 2025 · Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). Zongertinib is an oral ...
Clinical Practice Topics | The New England Journal of Medicine
Recognizing Historical Injustices in Medicine and the Journal Tobacco Use Reduction Additional Topics A Accountable Care Organizations Acute Coronary Syndromes Acute Kidney Injury Addiction
Lorundrostat Efficacy and Safety in Patients with Uncontrolled ...
Apr 23, 2025 · Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited.